ALNY Stock Analysis: Buy, Sell, or Hold?
ALNY - Alnylam Pharmaceuticals, Inc.
$301.64
13.46 (4.67%)
▲
5d:
+7.0%
30d:
+1.41%
90d:
-2.08%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When ALNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALNY shows positive signals but monitor for confirmation. Market pricing in 7.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ALNY shows positive signals but monitor for confirmation. Market pricing in 7.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$670.15
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$416.11
27.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALNY is currently trading at $301.64, which is considered oversold relative to its 30-day fair value range of $285.44 to $299.48. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.9) compared to its historical average (26.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ALNY is in a strong downtrend. The price is approaching resistance at $302.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ALNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $436.32 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALNY is in a strong downtrend. The price is approaching resistance at $302.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ALNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $436.32 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$285.44 -
$299.48
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 51.4% below Wall St target ($436.32)
Trading Range Analysis
30-Day Trading Range
$285.44 -
$299.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$273.11
Resistance Level
$302.85
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.94
Wall Street Target
$436.32
(+51.4%)
Revenue Growth (YoY)
96.4%
Profit Margin
12.6%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
20.9 vs 26.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$265.99
(-8%)
2-Year Target
$245.51
(-15%)
3-Year Target
$226.60
(-21%)
3-Yr Target (if PE normalizes)
(PE: 21→27)
$287.92
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 44.8%)
$910.63
(+216%)
Base:
(SPY PE: 20.9, Growth: 44.8%)
$875.32
(+204%)
Bear:
(PE: 17.8, Growth: 44.8%)
$744.02
(+158%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Forward PE: 30.67 | Forward EPS (Implied): $9.39
Bull Case
$347.98
(+21%)
Analyst growth 15.0%, PE expands to 32.2
Base Case
$288.18
(0%)
Market implied 0.0%, PE stable at 30.7
Bear Case
$220.46
(-24%)
Severe decline -15.0%, PE contracts to 27.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.9 to 26.6
Stabilization Target:
$366.16
(+27.1%)
PE Expansion Potential:
+27.1%
Share & Embed Analysis
Last updated: June 24, 2026 11:47 AM ET
Data refreshes hourly during market hours. Next update: 12:47 PM
Data refreshes hourly during market hours. Next update: 12:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Melissa Mclaughlin
SELL
2286 shares
2026-04-06
Melissa Mclaughlin
SELL
1624 shares
2026-04-02
Kevin Joseph Fitzgerald
SELL
1652 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 62 BUY |
